United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by State of Alaska Department of Revenue
State of Alaska Department of Revenue lowered its position in United Therapeutics Co. (NASDAQ:UTHR) by 62.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,651 shares of the biotechnology company’s stock after selling 7,721 shares during the quarter. State of Alaska Department of Revenue’s holdings in United Therapeutics were worth $363,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently modified their holdings of UTHR. Norges Bank purchased a new stake in United Therapeutics in the fourth quarter valued at approximately $54,233,000. Pictet Asset Management Ltd. lifted its stake in United Therapeutics by 64.0% in the first quarter. Pictet Asset Management Ltd. now owns 266,163 shares of the biotechnology company’s stock valued at $31,240,000 after buying an additional 103,840 shares during the last quarter. Macquarie Group Ltd. lifted its stake in United Therapeutics by 855.9% in the fourth quarter. Macquarie Group Ltd. now owns 112,800 shares of the biotechnology company’s stock valued at $12,284,000 after buying an additional 101,000 shares during the last quarter. First Trust Advisors LP lifted its stake in United Therapeutics by 7.8% in the first quarter. First Trust Advisors LP now owns 1,290,590 shares of the biotechnology company’s stock valued at $151,477,000 after buying an additional 93,786 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. lifted its stake in United Therapeutics by 26.0% in the first quarter. Robeco Institutional Asset Management B.V. now owns 402,159 shares of the biotechnology company’s stock valued at $47,204,000 after buying an additional 83,037 shares during the last quarter. Institutional investors own 96.32% of the company’s stock.
In related news, Director Raymond Dwek sold 3,750 shares of the company’s stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $76.11, for a total transaction of $285,412.50. Following the transaction, the director now owns 3,750 shares of the company’s stock, valued at $285,412.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard Giltner sold 5,000 shares of the company’s stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $79.05, for a total value of $395,250.00. Following the transaction, the director now directly owns 5,000 shares in the company, valued at approximately $395,250. The disclosure for this sale can be found here. 8.20% of the stock is owned by corporate insiders.
Shares of United Therapeutics stock traded up $0.72 during trading hours on Friday, hitting $77.60. 578,781 shares of the company were exchanged, compared to its average volume of 527,299. United Therapeutics Co. has a 1 year low of $74.31 and a 1 year high of $130.00. The company has a quick ratio of 6.84, a current ratio of 7.19 and a debt-to-equity ratio of 0.45. The firm has a 50-day simple moving average of $78.44. The firm has a market capitalization of $3.40 billion, a PE ratio of 5.80 and a beta of 1.04.
United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported ($11.32) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.64 by ($13.96). United Therapeutics had a negative return on equity of 5.78% and a negative net margin of 9.36%. The company had revenue of $362.70 million for the quarter, compared to analysts’ expectations of $335.72 million. During the same quarter last year, the company earned $3.76 EPS. United Therapeutics’s revenue for the quarter was down 6.8% compared to the same quarter last year. On average, research analysts predict that United Therapeutics Co. will post -5.03 EPS for the current year.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Recommended Story: How is inflation measured?
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.